Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings, Inc.

AHRM is a specialty CRO that focuses on Health Economics and Outcomes Research. The company integrates and conducts clinical trials and outcomes research across various therapeutic areas.

Applied Healthcare Research Management Inc. (AHRM)

Signant Health provides clinical trial technology and services, focusing on clinical data collection, patient engagement, clinical IP management, and analytics. Signant Health offers tailored solutions to meet specific protocol requirements.

Signant Health

Flask Data is a Digital Clinical Research Organization that specializes in executing medtech and digital therapeutics studies.

Flask Data

Medpace is a drug and biologic contract research organization (CRO) that offers comprehensive services for clinical development, providing integrated solutions through a full-service model.

Metric
Company Name	Medpace Holdings, Inc.	Applied Healthcare Research Management Inc. (AHRM)	Signant Health	Flask Data
Symbol	MEDP
MSH ID	COM:MEDPACE	COM:AHRMINC	COM:SIGNANTHEALTH	IO:FLASKDATA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Diagnostics & Research	Contract Research Organization (CRO)	Clinical Research and Development	Clinical Research
Country	US	US	US	US
Stage
Employee Count	5.80K		1.00K
Website	medpace.com	ahrminc.com	signanthealth.com	flaskdata.io
LinkedIn		applied-healthcare-resource-management
Founders

Metric
Market Cap	12.98B
Enterprise Value
Monthly Web Traffic		1	43.77K
Web Traffic Growth			0.55
Valuation
Raised Capital

Metric
Revenue	1.89B
Revenue (LTM)
Revenue (NTM)
Gross Profit	524.50M
EBITDA	365.08M
Operating Income	336.82M
Net Income	282.81M
EPS	9.21
Diluted EPS	8.88
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.29
Operating Profit Margin	0.19
EBITDA Margin	0.19
Net Profit Margin	0.17
Return on Equity	0.64
Return on Assets	0.18
Return on Capital Employed	0.46

COM:MEDPACE

Medpace

Last Close

341.82

22/11 21:00

Market Cap

12.98B

Beta: -

Volume Today

351.39K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	33.19
P/B Ratio	19.25
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.05
EV Multiple	37.01

Metric
Days Sales Outstanding	59.98
Days Payables Outstanding	8.29
Days Inventory Outstanding
Operating Cycle	57.75
Cash Conversion Cycle	49.21
Asset Turnover	1.14

Metric
Operating Cash Flow	433.37M
Free Cash Flow	396.73M
Cash Flow to Debt	3.51
Operating Cash Flow/Sales	0.27
Free Cash Flow Yield	0.04

Metric
Cash & Equivalents	245.45M
Accounts Receivable	-48.28M
Inventory
Goodwill	662.40M
Debt to Capitalization	0.44
Debt to Assets	0.27
Current Ratio	0.53
Quick Ratio	0.88

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue
SG&A to Revenue